Patrick Harris

Damn that MexAB-OprM 😢 pubmed.ncbi.nlm.nih.gov/41251222/ @LondonUmejiaku

2026 International AMR Symposium: Seoul, S Korea, 25-27 Aug. Bringing together leading researchers and industry experts, with a focus on epidemiology, therapeutics, molecular mechanisms and novel targets for #AMR pathogens symposium2026.imweb.me

Implementation of the BIOFIRE Meningitis/Encephalitis Panel: A Mixed-Methods Implementation Study in a Nonmetropolitan Tertiary Hospital academic.oup.com/ofid/article/1… @davidantibiotic

Search is full of ads and wrong answers. Every other email is an ad. Prime Video charges you and shows ads. Paramount? Ads. Peacock? YouTube? Hulu? Ads followed by more ads. Netflix full of ads. Meta and X, every other thing is an ad. Pinterest is nothing but ads. AI is in everything. AI finishes sentences incorrectly and won’t stop. AI reads your email and search history to target you with more ads. Every time you open an app or visit a site there’s an update making it worse. In a hurry? First, click here to agree to terms you don’t have time to read and must accept. You need an account to do that. Change your temporary password. Enter your 2FA code. Check your email and enter that code. Now use a passkey. Your password is too simple to remember. Change it. No, not like that. Now log on. Enter your 2FA code. Check your email for a code… Welcome back! We’ve updated our terms of service and privacy policy (you have none). Subscribe to the site. Subscribe to Netflix. Subscribe to toilet paper. Subscribe to these groceries. Pay a membership fee for the right to subscribe then tip your driver who delivers the subscriptions your membership lets you subscribe to. Time to work? We’ve got to update your laptop and will slow down everything you do until you agree to update. But first, click here to agree. Update installed — your laptop’s broken now. It doesn’t matter, since your boss just replaced you with AI. Go to your phone to complain on social media. Wait, your phone needs an update so we can add more AI. Click here. Oh sorry, your phone can’t handle this update. Now it’s useless. Go get the newest phone. Here’s a text from a friend, an email, a voice mail they left three days ago but you didn’t see until now because of sync problems with the cloud. It’s their GoFundMe. Their MLM. Their Patreon. Never mind, you didn’t respond to their text within 9 minutes and now you’re no longer friends. They blocked you. Make new friends. Download this app to find people in your area. In your neighborhood. On your street. Two doors down from you. Do you know this person yet, we think you’d get along. You need an account to use this app. That username is taken. Enter a password. Not that one, you used it on another site. You need to be connected to WiFi to download the app. Allow the app to connect to other devices on your network. Allow the app to access your contacts, know your precise location, store your credit card details. Oops, sorry, we got hacked now all that info is available on the web. There’s a class action suit. You can join. It’ll take a decade to get your $3.73 share of the ten billion settlement. We’ll send it via PayPal or deposit it to your bank, just tell us those details. Oh no, another hack. That info is circulating now, too. Here’s a spam call, a spam email, a spam text. Why are you angry? Why are you talking about getting rid of your phone? Why don’t you like AI, it lets us make all of this easier? Do you know how ridiculous that sounds? This is progress. You’ll be left behind. Do you want to be left behind? Do you???

Implementation of pathogen genomics in clinical microbiology laboratories journals.asm.org/doi/10.1128/cm…

Super interesting: Ceftriaxone-R E.coli / K.pneumoniae BSI(n=163) 2022-24 🧬blaCTX-M+:85.3% 🧬 No-blaCTX-M:14.7% ⚠️🔼 No-blaCTX-M ceftriaxone R ⏱ CTX-M+:faster optimal therapy 💡 Molecular testing still useful for ESBL detection→always confirm with AST academic.oup.com/ofid/article/1…

Super interesting cUTI case with Klebsiella pneumoniae treated with pip tazo. Day 1:S to pip tazo Day 7:R to pip tazo 👉 Classic reminder: heteroresistance can hide in plain sight Even BMD may fail to detect it reliably 👉 Clinically linked to treatment failure in reported cases thelancet.com/journals/lanmi…

Researchers paid $1.06 billion to five academic publishers from 2015-2018 to publish their papers. Academic publishers sold the same papers back to researchers for $2 billion.

Empirical Antibiotic Activity and Outcomes in Pediatric Gram-Negative Bloodstream Infections: A Rank-based Composite Outcome Analysis ✅ Just Accepted ✍️ @DrSophCHWen 🔗 bit.ly/4ejsUYV

Differences in clinical outcomes among patients with mold fungemia 🔁 Repost ✍️ @adm_stewart 🔗 bit.ly/4sryNrv

@BradSpellberg @ABsteward Couldn’t agree more - we should all be more accepting of how much we don’t know for sure and encourage enrolment into clinical trials where evidence is lacking

See link at academic.oup.com/cid/article/do…

Our @wikiguidelines letter to the editor regarding the controversy between IDSA and ATS on CAP guidelines is now published. Time for societies to modernize their approach to guidelines to STOP creating care standards based on opinions. @ABsteward @DrToddLee @AnilMakam @medrants

@ABsteward @DrToddLee @ESCMID Steve summed up the current state of things well; MERINO was underpowered but the alarming mortality signal at interim analysis was a whisker off our stopping boundary - so we couldn’t in conscience continue to enrol with equipoise; AST errors with PTZ compounded our concerns

▶️💥Tick tock, AMR clock: how should I treat my next ESBL bacteraemia patient? Excellent talk by Prof Tong Carbapenem sparing drug? Do we need it? Data? Does it increase CRE? Bayesian priori Next patient with ESBL : would you give pip tazo or Mero ? #ESCMIDGlobal2026

@JohnGolf_CA @ABsteward @jesusrbano 💯 agree

@padstamundo @ABsteward @jesusrbano CEFMEC deserved better than poster hall. 2% vs 5.2% mortality is massive - finally have real carbapenem-sparing options alongside ASTARTÉ.

▶️🔛Sepsis: year in review 🔥 Breaking news: ASTARTÉ RCT ( In press-Lancet) Temocillin is non-inferior to carbapenems for the targeted treatment of bacteremia due to cephalosporin-resistant Enterobacterales Slides credits to @jesusrbano #ESCMIDGlobal2026

@davidantibiotic Other important differences - MERINO included patients with septic shock, PETERPEN used 3h infusions - may have made a difference? PETERPEN also had an overall much higher mortality (14%) ...

@davidantibiotic discusses the implications from PETERPEN and MERINO.. how do we make sense of the differences? outlines the important of OXA-1 on PTZ MICs... were there differences in the organisms in each trial? pubmed.ncbi.nlm.nih.gov/33106863/

Looking forward to the ESBL RCT session #ESCMIDGlobal2026 - PETERPEN, @MerinoTrial and ASTARTE in a tussle to determine how we should treat ESBL bloodstream infections... great to see more trials tackling this important question and seeking alternatives to carbapenems

@davidantibiotic We have also analysed MERINO with a win-ratio to explore outcomes beyond mortality alone - still seemed to suggest improved outcomes with meropenem pubmed.ncbi.nlm.nih.gov/38306577/

#ESCMIDGlobal2026 ASTARTE RCT, temocillin vs carbapenem - was presented last year, now post hoc analysis comparing ertapenem vs meropenem-> prim. endpoint of clinical success; NI shown in overall study; no obvious differences if erta vs mero used, some imbalances however..